1.Pure Basaloid Squamous Cell Carcinoma of the Uterine Cervix: A Case Report.
Yong Soon KWON ; Yong Man KIM ; Ga Won CHOI ; Young Tak KIM ; Joo Hyun NAM
Journal of Korean Medical Science 2009;24(3):542-545
Basaloid squamous cell carcinoma of the uterine cervix is an extremely rare malignancy of the female genital tract with a poorer clinical outcome than squamous cell carcinoma of the uterine cervix. We report a case of pure basaloid squamous cell carcinoma of the uterine cervix. A 70-yr-old woman with vaginal bleeding was referred to our institute. A basaloid squamous cell carcinoma of the uterine cervix, of International Federation of Gynecology and Obstetrics (FIGO) stage Ib1, was diagnosed by a loop electrosurgical excision procedure cone biopsy. A radical hysterectomy was performed, along with bilateral salpingo-oophorectomy, pelvic lymph node dissection, and para-aortic lymph node sampling. Pathologic findings were consistent with a basaloid squamous cell carcinoma confined to the cervix without an extracervical tumor. No further treatment was administered and there was no clinical evidence of recurrence during the 12 months of follow-up. Follow-up for the patient is ongoing. Although basaloid squamous cell carcinoma of the uterine cervix is thought to behave aggressively, accumulation of data on these rare tumors is necessary to determine whether their behavior differs significantly from that of conventional cervical squamous cell carcinoma of similar clinical stage. These data would be useful for defining the best diagnosis and treatment for these rare tumors.
Aged
;
Carcinoma, Squamous Cell/*diagnosis/pathology/surgery
;
Colonoscopy
;
Female
;
Humans
;
Hysterectomy
;
Magnetic Resonance Angiography
;
Uterine Cervical Neoplasms/*diagnosis/pathology/surgery
3.Granulocytic sarcoma of uterine cervix: report of a case.
Qiu-Yu LIU ; Mei XU ; Yuan-Rui HAO ; Li LI ; Ling-Fei KONG
Chinese Journal of Pathology 2010;39(11):773-774
Adult
;
Carcinoma, Small Cell
;
metabolism
;
pathology
;
Diagnosis, Differential
;
Female
;
Follow-Up Studies
;
Humans
;
Hysterectomy
;
Leukosialin
;
metabolism
;
Lymphoma
;
metabolism
;
pathology
;
Peroxidase
;
metabolism
;
Sarcoma, Myeloid
;
metabolism
;
pathology
;
surgery
;
Uterine Cervical Neoplasms
;
metabolism
;
pathology
;
surgery
;
Uterine Cervicitis
;
metabolism
;
pathology
5.Major clinical research advances in gynecologic cancer in 2014.
Dong Hoon SUH ; Kyung Hun LEE ; Kidong KIM ; Sokbom KANG ; Jae Weon KIM
Journal of Gynecologic Oncology 2015;26(2):156-167
In 2014, 9 topics were selected as major advances in clinical research for gynecologic oncology: 2 each in cervical and corpus cancer, 4 in ovarian cancer, and 1 in breast cancer. For cervical cancer, several therapeutic agents showed viable antitumor clinical response in recurrent and metastatic disease: bevacizumab, cediranib, and immunotherapies including human papillomavirus (HPV)-tumor infiltrating lymphocytes and Z-100. The HPV test received FDA approval as the primary screening tool of cervical cancer in women aged 25 and older, based on the results of the ATHENA trial, which suggested that the HPV test was a more sensitive and efficient strategy for cervical cancer screening than methods based solely on cytology. For corpus cancers, results of a phase III Gynecologic Oncology Group (GOG) 249 study of early-stage endometrial cancer with high-intermediate risk factors are followed by the controversial topic of uterine power morcellation in minimally invasive gynecologic surgery. Promising results of phase II studies regarding the effectiveness of olaparib in various ovarian cancer settings are summarized. After a brief review of results from a phase III study on pazopanib maintenance therapy in advanced ovarian cancer, 2 outstanding 2014 ASCO presentations cover the topic of using molecular subtypes in predicting response to bevacizumab. A review of the use of opportunistic bilateral salpingectomy as an ovarian cancer preventive strategy in the general population is presented. Two remarkable studies that discussed the effectiveness of adjuvant ovarian suppression in premenopausal early breast cancer have been selected as the last topics covered in this review.
Biomedical Research/*trends
;
Endometrial Neoplasms/drug therapy/pathology/surgery
;
Female
;
Genital Neoplasms, Female/diagnosis/*therapy
;
Humans
;
Ovarian Neoplasms/drug therapy/pathology/surgery
;
Uterine Cervical Neoplasms/drug therapy/pathology/surgery
6.Cervical carcinoid with high-grade intraepithelial neoplasia: report of a case.
Hai LI ; Fang BAO ; Yu-fei LI ; Yi-long DAI ; Ying XIANG ; Zhi-hong ZHANG
Chinese Journal of Pathology 2013;42(5):347-348
Adult
;
Breast Neoplasms
;
metabolism
;
pathology
;
secondary
;
Carcinoid Tumor
;
metabolism
;
pathology
;
surgery
;
Carcinoma, Adenoid Cystic
;
pathology
;
Carcinoma, Lobular
;
metabolism
;
pathology
;
secondary
;
Cervical Intraepithelial Neoplasia
;
metabolism
;
pathology
;
surgery
;
Chromogranin A
;
metabolism
;
Diagnosis, Differential
;
Female
;
Humans
;
Hysterectomy
;
Keratins
;
metabolism
;
Neoplasms, Multiple Primary
;
metabolism
;
pathology
;
surgery
;
Ovarian Neoplasms
;
metabolism
;
pathology
;
Sex Cord-Gonadal Stromal Tumors
;
metabolism
;
pathology
;
Synaptophysin
;
metabolism
;
Uterine Cervical Neoplasms
;
metabolism
;
pathology
;
surgery
7.Value of Second Pass in Loop Electrosurgical Excisional Procedure.
Kidong KIM ; Soon Beom KANG ; Hyun Hoon CHUNG ; Tack Sang LEE ; Jae Weon KIM ; Noh Hyun PARK ; Yong Sang SONG
Journal of Korean Medical Science 2009;24(1):110-113
The aim of this study was to compare the rate of incomplete resection and treatment outcome of the second-pass technique with those of single-pass technique in loop electrosurgical excisional procedure (LEEP). From 1997 to 2002, 683 women were diagnosed as squamous dysplasia via LEEP in our institution. Age, parity, LEEP technique, grade of lesion, glandular extension, margin status, residual tumor and recurrence were obtained by reviewing medical records. Positive margin was defined as mild dysplasia or higher grade lesions at resection margin of the LEEP specimen. In women who underwent hysterectomy, residual tumor was defined as mild dysplasia or higher grade lesions in hysterectomy specimen. In women who did not underwent hysterectomy, Pap smear more than atypical squamous cells of undetermined significance or biopsy result more than mild dysplasia within two years after LEEP were regarded as cytologic or histologic recurrences, respectively. Treatment failure of LEEP was defined as residual tumor or histologic recurrence. The second-pass technique significantly reduced the endocervical margin positivity (odds ratio [OR], 0.36; 95% confidence interval [CI], 0.21-0.63). However, the second-pass technique did not reduce the treatment failure (OR, 0.62; 95% CI, 0.29-1.32). In conclusion, the second-pass technique markedly reduced the endocervical margin positivity, but did not reduce the treatment failure rate of LEEP.
Adult
;
Cervical Intraepithelial Neoplasia/pathology/*surgery
;
Electrosurgery/*methods
;
Female
;
Humans
;
Hysterectomy
;
Medical Records
;
Middle Aged
;
Neoplasm Recurrence, Local/diagnosis/epidemiology
;
Neoplasm, Residual/diagnosis/epidemiology
;
Odds Ratio
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Severity of Illness Index
;
Uterine Cervical Neoplasms/pathology/*surgery
8.Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.
Mamiko ONUKI ; Koji MATSUMOTO ; Manabu SAKURAI ; Hiroyuki OCHI ; Takeo MINAGUCHI ; Toyomi SATOH ; Hiroyuki YOSHIKAWA
Journal of Gynecologic Oncology 2016;27(1):e3-
OBJECTIVE: We conducted a pooled analysis of published studies to compare the performance of human papillomavirus (HPV) testing and cytology in detecting residual or recurrent diseases after treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3). METHODS: Source articles presenting data on posttreatment HPV testing were identified from the National Library of Medicine (PubMed) database. We included 5,319 cases from 33 articles published between 1996 and 2013. RESULTS: The pooled sensitivity of high-risk HPV testing (0.92; 95% confidence interval [CI], 0.90 to 0.94) for detecting posttreatment CIN 2 or worse (CIN 2+) was much higher than that of cytology (0.76; 95% CI, 0.71 to 0.80). Co-testing of HPV testing and cytology maximized the sensitivity (0.93; 95% CI, 0.87 to 0.96), while HPV genotyping (detection of the same genotype between pre- and posttreatments) did not improve the sensitivity (0.89; 95% CI, 0.82 to 0.94) compared with high-risk HPV testing alone. The specificity of high-risk HPV testing (0.83; 95% CI, 0.82 to 0.84) was similar to that of cytology (0.85; 95% CI, 0.84 to 0.87) and HPV genotyping (0.83; 95% CI, 0.81 to 0.85), while co-testing had reduced specificity (0.76; 95% CI, 0.75 to 0.78). For women with positive surgical margins, high-risk HPV testing provided remarkable risk discrimination between test-positives and test-negatives (absolute risk of residual CIN 2+ 74.4% [95% CI, 64.0 to 82.6] vs. 0.8% [95% CI, 0.15 to 4.6]; p<0.001). CONCLUSION: Our findings recommend the addition of high-risk HPV testing, either alone or in conjunction with cytology, to posttreatment surveillance strategies. HPV testing can identify populations at greatest risk of posttreatment CIN 2+ lesions, especially among women with positive section margins.
Cervical Intraepithelial Neoplasia/pathology/surgery/*virology
;
Female
;
Humans
;
Neoplasm Recurrence, Local/*virology
;
Neoplasm, Residual
;
Papillomaviridae/*isolation & purification
;
Papillomavirus Infections/complications/*diagnosis
;
Predictive Value of Tests
;
Risk Assessment/methods
;
Sensitivity and Specificity
;
Uterine Cervical Neoplasms/pathology/surgery/*virology
9.Villoglandular adenocarcinoma of cervix:a clinicopathological study.
Zheng-cao LIU ; Lu ZHENG ; Yun-long HUO ; Xiang-hong YANG ; Ai-feng GAO ; Xiu-juan CUI
Chinese Journal of Pathology 2010;39(5):338-339
Adenocarcinoma
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Clear Cell
;
metabolism
;
pathology
;
Adult
;
CA-125 Antigen
;
metabolism
;
Carcinoembryonic Antigen
;
metabolism
;
Cervical Intraepithelial Neoplasia
;
metabolism
;
pathology
;
surgery
;
Cystadenocarcinoma, Serous
;
metabolism
;
pathology
;
Diagnosis, Differential
;
Female
;
Follow-Up Studies
;
Humans
;
Hysterectomy
;
Ki-67 Antigen
;
metabolism
;
Lymph Node Excision
;
Membrane Proteins
;
metabolism
;
Neoplasm Invasiveness
;
Uterine Cervical Neoplasms
;
metabolism
;
pathology
;
surgery
10.Müllerian duct anomalies and their effect on the radiotherapeutic management of cervical cancer.
Madhup RASTOGI ; Swaroop REVANNASIDDAIAH ; Pragyat THAKUR ; Priyanka THAKUR ; Manish GUPTA ; Manoj K GUPTA ; Rajeev K SEAM
Chinese Journal of Cancer 2013;32(8):434-440
Radiotherapy plays a major role in the treatment of cervical cancer. A successful radiotherapy program integrates both external beam and brachytherapy components. The principles of radiotherapy are strongly based on the anatomy of the organ and patterns of local and nodal spread. However, in patients with distorted anatomy, several practical issues arise in the delivery of optimal radiotherapy, especially with brachytherapy. Müllerian duct anomalies result in congenital malformations of the female genital tract. Though being very commonly studied for their deleterious effects on fertility and pregnancy, they have not been recognized for their potential to interfere with the delivery of radiotherapy among patients with cervical cancer. Here, we discuss the management of cervical cancer among patients with Müllerian duct anomalies and review the very sparse amount of published literature on this topic.
Brachytherapy
;
Diagnostic Imaging
;
Female
;
Genital Diseases, Female
;
diagnosis
;
diagnostic imaging
;
pathology
;
Humans
;
Magnetic Resonance Imaging
;
Mullerian Ducts
;
abnormalities
;
diagnostic imaging
;
pathology
;
Radiography
;
Radiosurgery
;
Radiotherapy
;
methods
;
Uterine Cervical Neoplasms
;
radiotherapy
;
surgery